Powered by the Scientific Committee as its academic engine and driven by the bidirectional data feedback between IND trials and IITs (Investigator-Initiated Trials), Harbour Medical continuously drives the efficient translation of innovative therapies from laboratory to clinic.
Harbour Medical is the core business platform of Harbour BioMed dedicated to clinical development and medical services, committed to providing end-to-end solutions for global innovative therapies — from early clinical validation through post-marketing studies.
The platform simultaneously undertakes clinical trial programs across Harbour BioMed's full internal product pipeline and provides clinical development services for external partners, encompassing co-development, strategic partnerships, and clinical CRO engagement models.
Powered by the Scientific Committee as its academic engine and driven by the bidirectional data feedback between IITs (Investigator-Initiated Trials) and IND trials, Harbour Medical continuously drives the efficient translation of innovative therapies from laboratory to clinic.
Leveraging full-lifecycle clinical development capabilities, the platform efficiently advances internal pipeline candidates from First-in-Human (FIH) through regulatory approval; concurrently, it provides global partners with co-development, end-to-end services, and strategic partnerships — combining professional operations with shared risk to accelerate patient access to innovative therapies.
Harbour Medical undertakes comprehensive clinical trial design and execution across Harbour BioMed's internal product pipeline, covering the full lifecycle from First-in-Human (FIH) studies to Pivotal Registration studies, ensuring efficient and compliant advancement toward regulatory submission.
Providing professional clinical development services for global biopharmaceutical partners, including but not limited to:
Dr. Jingsong Wang, is our Principal Founder, Chairman and Chief Executive Officer. Prior to founding our company, Dr. Wang served as Head of China R&D and Head of Translational Medicine, Asia Pacific, at Sanofi. He is a former attending physician and clinical fellow at Harvard Medical School. Dr. Wang received his Ph.D. in Molecular Pharmacology from China Pharmaceutical University and completed a Molecular Immunology Research Fellowship at Dr. Laurie Glimcher's laboratory at the Harvard School of Public Health.
Dr. Adam Zong is President of Harbour BioMed. Based in Shanghai, he is responsible for strengthening the Company's internal product pipeline, advancing the strategic development of its overall portfolio, and leading asset strategy and partnership initiatives. He will also play a key role in aligning cross-functional efforts to accelerate development timelines and maximize the value of the Company's pipeline.
Dr. Zong brings more than 20 years of global biopharma leadership experience, with a strong track record in portfolio strategy, commercial operations, and business development. His experience spans both multinational pharmaceutical companies and emerging biotechnology organizations. Prior to joining Harbour BioMed, Dr. Zong served as Principal Consultant at Arc Nouvel Clinical Development Consulting. He also served as the founding Chief Executive Officer of Hengrui Therapeutics U.S., where he led the company's global expansion. Earlier in his career, he held senior leadership roles at Merck & Co., Bristol Myers Squibb, Schering-Plough, and Pfizer, where he managed global franchises, oversaw large-scale commercial portfolios, and led significant business development, licensing, and M&A transactions.
Dr. Zong received his Ph.D. in Oncology and Virology from Rockefeller University and holds an MBA in Finance and Entrepreneurial Management from The Wharton School of the University of Pennsylvania.
Dr. Jenny Xie is Chief Scientific Officer, Immunology and Head of Global External Innovation of Harbour BioMed. Based in Shanghai, she is responsible for Harbour BioMed's global external innovation strategy in immunology, managing ongoing strategic collaborations with key partners, as well as identifying and pursuing new partnership opportunities. Additionally, she will oversee all activities at the company's Harbour BioMed-AstraZeneca Innovation Lab in Beijing.
Dr. Xie brings more than 25 years of experience in the biopharmaceutical industry. Prior to joining Harbour BioMed, she served as Executive Director and Head of Discovery Immunology at Bristol Myers Squibb, where she led research efforts in autoimmune diseases and contributed to the discovery, evaluation, and clinical translation of novel therapeutic approaches. Prior to that, she also held scientific leadership roles at Merck, building extensive experience in early-stage research and development.
Dr. Xie received her Ph.D. in Immunology from Boston University School of Medicine and her bachelor's degree in Biology from Fudan University.
Dr. Bob Zhang is President of Metabolic Disease Franchise at Harbour BioMed. Based in Shanghai, he leads the franchise's strategy and operations, overseeing portfolio development, research and development, organizational growth, strategic collaborations, and NewCo incubation to accelerate the delivery of transformative therapies for patients.
Dr. Zhang is a physician-scientist and biotech entrepreneur with more than 20 years of leadership experience in metabolic and liver disease research and development. Prior to joining Harbour BioMed, he served as Co-founder and Chief Executive Officer of Epigenic Therapeutics, Chief Executive Officer of Kunming Biomed International, and Director of Translational Medicine at Sanofi. Throughout his career, he has led drug discovery, translational pharmacology, and early clinical development programs across biotechnology companies, multinational pharmaceutical organizations, and CROs, while also contributing to biotech company formation, strategy, and growth.
Dr. Zhang received his M.D. from Dalian Medical University and his Ph.D. from the University of Sydney, and completed executive management training at CEIBS (China Europe International Business School).
Grounded in scientific evidence to ensure rigorous trial design, reliable data, and clinically meaningful conclusions
Coordinated review by medical, statistical, pharmacological, and regulatory experts across the full trial lifecycle
Tracking frontier scientific advances to drive the application of adaptive designs, real-world evidence, and other innovative methodologies
A bidirectional drive between IND trials and IITs (Investigator-Initiated Trials), accelerating the overall advancement of the product pipeline through scientific insights:
Leveraging clinical data and experience from IITs to optimize IND trial design, patient stratification strategies, and endpoint selection, reducing development risk and improving success rates
Rapidly and cost-effectively exploring new indications, combination regimens, and biomarker hypotheses through investigator-initiated trials, providing reference clinical evidence for subsequent IND programs
Corresponding capabilities span multiple stages from strategy development to regulatory submission, with efficiency gains stacking cumulatively to 50% overall.
Key deliverables routinely achieve 2–4× acceleration (e.g., Protocol 8→2 weeks, TFL 8→2 weeks, CSR 1 month→1 week), directly translating into earlier data readouts and accelerated time-to-market.
Site selection accuracy +30–50%, compliance risk −30%, project delays −30–50%: efficiency and quality improve in tandem.
ICSR entry and document quality checks at minute-level or even second-level granularity, transforming reactive remediation into proactive, real-time control.
Digital twins advance "cost-efficiency optimization" to "failure rate reduction;" virtual synthetic control arms provide pathways unavailable through traditional methods in rare disease, pediatric, and ethically constrained settings.
